Literature DB >> 17899014

Effects of receptor density on Nociceptin/OrphaninFQ peptide receptor desensitisation: studies using the ecdysone inducible expression system.

T A Barnes1, J McDonald, D J Rowbotham, T L Duarte, D G Lambert.   

Abstract

Pretreatment of the G-protein coupled nociceptin receptor (NOP) with nociceptin/orphaninFQ (N/OFQ) produces desensitisation. The influences of receptor expression and genomic effects are largely unknown. We have used an ecdysone-inducible NOP expression system in a CHO line (CHO INDhNOP) to examine the effects of N/OFQ pretreatment upon receptor density, GTPgamma[35S] binding, cAMP formation and NOP-mRNA. CHO(INDhNOP) induced with 5 and 10 microM PonasteroneA (PonA) for 20 h produced NOP densities (Bmax) of 194 and 473 fmol. mg(-1) protein, respectively. This was accompanied by decreased NOP mRNA. The lower Bmax is typical of the central nervous system. Pretreatment with 1 microM N/OFQ significantly (p < 0.05) reduced Bmax at 5 and 10 microM PonA to 100 and 196 fmol. mg(-1) protein, respectively. There was no change in binding affinity. Along with the reduction in Bmax), potency and efficacy for N/OFQ-stimulated GTPgamma[35S] binding were also reduced (5 microM PonA: pEC50-control = 8.55 +/- 0.06, pretreated = 7.88 +/- 0.07; Emax-control = 3.52 +/- 0.43, pretreated = 2.48 +/- 0.10; 10 microM PonA: pEC50-control = 8.41 +/- 0.18, pretreated = 7.76 +/- 0.03; Emax-control = 5.07 +/- 0.17, pretreated = 3.38 +/- 0.19). For inhibition of cAMP formation, there was a reduction in potency (5 microM PonA: pEC50-control = 9.78 +/- 0.08, pretreated = 8.92 +/- 0.13; 10 microM PonA: pEC50-control = 9.99 +/- 0.07, pretreated = 9.04 +/- 0.14), but there was no reduction in efficacy. In addition, there were 39 and 31% reductions in NOP mRNA at 5 and 10 microM PonA, respectively, but these measurements were made following concurrent N/OFQ challenge and PonA induction. In CHO INDhNOP, we have shown a reduction in cell surface receptor numbers and a reduction in functional coupling after N/OFQ pretreatment. This was observed at pseudo-physiological and supraphysiological receptor densities. Moreover, we also report a reduction in NOP mRNA, but further studies are needed which include 'pulsing' PonA and desensitizing following wash-out.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17899014     DOI: 10.1007/s00210-007-0189-z

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  36 in total

Review 1.  Cellular actions of nociceptin: transduction mechanisms.

Authors:  B E Hawes; M P Graziano; D G Lambert
Journal:  Peptides       Date:  2000-07       Impact factor: 3.750

2.  Endogenous opioid receptor-like receptor in human neuroblastoma SK-N-SH cells: activation of inhibitory G protein and homologous desensitization.

Authors:  Z J Cheng; G H Fan; J Zhao; Z Zhang; Y L Wu; L Z Jiang; Y Zhu; G Pei; L Ma
Journal:  Neuroreport       Date:  1997-05-27       Impact factor: 1.837

3.  Nociceptin/orphanin FQ stimulates extracellular acidification and desensitization of the response involves protein kinase C.

Authors:  G Pei; K Ling; L Pu; M D Cunningham; L Ma
Journal:  FEBS Lett       Date:  1997-07-21       Impact factor: 4.124

4.  Functional expression, activation and desensitization of opioid receptor-like receptor ORL1 in neuroblastoma x glioma NG108-15 hybrid cells.

Authors:  L Ma; Z J Cheng; G H Fan; Y C Cai; L Z Jiang; G Pei
Journal:  FEBS Lett       Date:  1997-02-10       Impact factor: 4.124

5.  Regulation of STAT3 activity by G16-coupled receptors.

Authors:  Eddy H T Wu; Rico K H Lo; Yung H Wong
Journal:  Biochem Biophys Res Commun       Date:  2003-04-11       Impact factor: 3.575

6.  Ecdysone-inducible gene expression in mammalian cells and transgenic mice.

Authors:  D No; T P Yao; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

7.  Regulation of cyclic AMP-dependent response element-binding protein (CREB) by the nociceptin/orphanin FQ in human dopaminergic SH-SY5Y cells.

Authors:  Myung-Sunny Kim; Young-Pyo Cheong; Hong-Seob So; Kang-Min Lee; Yong Son; Chang-Soo Lee; Jae-Seung Yun; Raekil Park
Journal:  Biochem Biophys Res Commun       Date:  2002-03-01       Impact factor: 3.575

Review 8.  Post-opioid receptor adaptations to chronic morphine; altered functionality and associations of signaling molecules.

Authors:  Alan R Gintzler; Sumita Chakrabarti
Journal:  Life Sci       Date:  2006-03-06       Impact factor: 5.037

9.  Nociceptin/orphanin FQ and its receptor--potential targets for pain therapy?

Authors:  Hanns Ulrich Zeilhofer; Girolamo Calò
Journal:  J Pharmacol Exp Ther       Date:  2003-04-29       Impact factor: 4.030

10.  Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system.

Authors:  J McDonald; T A Barnes; H Okawa; J Williams; G Calo'; D J Rowbotham; D G Lambert
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

View more
  5 in total

1.  Modulation of silent and constitutively active nociceptin/orphanin FQ receptors by potent receptor antagonists and Na+ ions in rat sympathetic neurons.

Authors:  Saifeldin Mahmoud; Wojciech Margas; Claudio Trapella; Girolamo Caló; Victor Ruiz-Velasco
Journal:  Mol Pharmacol       Date:  2010-02-16       Impact factor: 4.436

Review 2.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

Review 3.  Cellular mechanisms of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N/OFQ.

Authors:  Courtney L Donica; Hibah O Awwad; Deepak R Thakker; Kelly M Standifer
Journal:  Mol Pharmacol       Date:  2013-02-08       Impact factor: 4.436

4.  Desensitisation of native and recombinant human urotensin-II receptors.

Authors:  Madura S Batuwangala; Girolamo Calo; Remo Guerrini; Leong L Ng; John McDonald; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-13       Impact factor: 3.000

5.  Nociceptin/Orphanin FQ (N/OFQ) conjugated to ATTO594: a novel fluorescent probe for the N/OFQ (NOP) receptor.

Authors:  M F Bird; R Guerrini; J M Willets; J P Thompson; G Caló; D G Lambert
Journal:  Br J Pharmacol       Date:  2018-11-06       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.